Sinobiopharma Seeks Patent for New ACE Inhibitor Formulation

| About: Sinobiopharma, Inc (SNBP)

Sinobiopharma (OTC:SNBP) has filed for a China patent covering capsule forms of new drug compounds containing Perindopril, an angiotensin-converting enzyme (ACE) inhibitor. ACE inhibitors are used to treat high blood pressure (hypertension) and heart attack in people with coronary artery disease.

Sinobiopharma says it is the first company in the world to manufacture and market Perindopril in capsule form. The patent application covers the method of preparation and stability for new drug compounds containing Perindopril.

Beside the new formulation, which Sinobiopharma promotes as easier to swallow, the company also says the new formulation has the competitive advantage of lower API costs, greater efficacy and fewer side effects than its competitors. Sinobiopharma plans to offer the new product later this year.

Disclosure: none.